반응식
C(OC([N:8]1[CH2:13][CH:12]=[C:11]([C:14]2[NH:15][C:16]([C:29]3[CH:34]=[CH:33][C:32]([C:35]([F:38])([F:37])[F:36])=[CH:31][CH:30]=3)=[C:17]([C:19]3[CH:24]=[CH:23][C:22]([C:25]([F:28])([F:27])[F:26])=[CH:21][CH:20]=3)[N:18]=2)[CH2:10][CH2:9]1)=O)(C)(C)C.[C:39](O)([C:41]([F:44])([F:43])[F:42])=O>>[F:27][C:25]([F:28])([F:26])[C:22]1[CH:21]=[CH:20][C:19]([C:17]2[N:18]=[C:14]([C:11]3[CH2:10][CH2:9][N:8]([C:13]4[C:39]([C:41]([F:44])([F:43])[F:42])=[CH:11][CH:10]=[CH:9][N:8]=4)[CH2:13][CH:12]=3)[NH:15][C:16]=2[C:29]2[CH:30]=[CH:31][C:32]([C:35]([F:38])([F:37])[F:36])=[CH:33][CH:34]=2)=[CH:24][CH:23]=1참가 물질
3
실험 절차
4-[4,5-Bis-(4-trifluoromethyl-phenyl)-1H-imidazol-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester from step (a) above was treated with TFA under the condition of Example 22(c) to give the title compound, which was used directly in the next step without additional purification. MS (ESI, positive ion) m/z: 438 (M+1).
출처 및 근거
- ORD 기록
- ord-b5d9ce4009784138ab2d08b4eca135d7
- 출처 데이터셋
- uspto-grants-2008_10
- 특허 번호
- US07439360B2
연결된 노트
불러오는 중…